Paris – A new era in the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) may be on the horizon, as research continues to highlight the potential of tolebrutinib to leisurely disability progression. Traditionally, assessing success in MS treatment has focused on relapse rates, but a growing body of evidence suggests that in nrSPMS, where relapses are less frequent, focusing on disability accumulation is crucial. This shift in perspective is driving the development of new therapeutic approaches and monitoring strategies, offering hope for individuals with this challenging form of the disease.
nrSPMS is characterized by a gradual worsening of neurological function independent of relapses, presenting a significant clinical challenge. Currently, there are limited approved treatment options specifically for this stage of the disease. Tolebrutinib, an oral therapy, is designed to modulate the immune system within the central nervous system, potentially addressing the underlying drivers of disability progression. The focus on disability progression as a primary outcome measure represents a significant change in how treatment efficacy is evaluated in this patient population.
Tolebrutinib’s Phase 3 Trial Results Demonstrate Benefit
Positive results from the HERCULES phase 3 study, published in the New England Journal of Medicine on April 8, 2025, demonstrated that tolebrutinib delayed disability progression in people with nrSPMS. The study involved 1131 patients with nrSPMS, who had not experienced clinical relapses in the previous 24 months and had documented evidence of disability accumulation, according to a report in Neurology Today. Robert Fox, MD, Vice Chair of Research at Cleveland Clinic’s Neurological Institute, and chair of the HERCULES global steering committee, stated that tolebrutinib “represents a new class of therapy for the treatment of multiple sclerosis.”
The drug works by targeting immunologic drivers of chronic inflammation behind the blood-brain barrier, a key factor in disability accumulation in MS. This mechanism of action differentiates tolebrutinib from existing therapies, which often focus on reducing relapse rates. The findings from the HERCULES study were initially presented at the ECTRIMS conference on September 20, 2024, in Copenhagen, Denmark, and further analyses were presented at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.
Regulatory Review and Potential Availability
Sanofi, the developer of tolebrutinib, is currently seeking regulatory approval for the drug in both the United States and Europe. The Food and Drug Administration (FDA) granted tolebrutinib Priority Review and Breakthrough Therapy designations for nrSPMS, which are intended to expedite the review process. However, the FDA has extended the review period, with a target action date of September 28, 2025, as initially reported. A regulatory submission dossier is also under review in the European Union, with a decision expected in the first quarter of 2026, according to Sanofi’s press release.
Despite the initial positive data, challenges have emerged. In December 2025, BioSpace reported that a patient in a separate Sanofi trial involving tolebrutinib died of post-treatment complications, potentially impacting the overall assessment of the drug’s safety profile. The FDA has also delayed approval application for secondary progressive multiple sclerosis (SPMS).
The Future of nrSPMS Treatment and Monitoring
The development of tolebrutinib and the emphasis on disability progression as a key outcome measure signal a significant shift in the approach to managing nrSPMS. As research continues, This proves likely that more sophisticated monitoring tools and biomarkers will be developed to better track disease progression and assess treatment response. This will allow clinicians to personalize treatment strategies and optimize outcomes for individuals living with this debilitating condition.
Looking ahead, the FDA’s decision on tolebrutinib’s application, expected in late September 2025, will be a critical milestone. The outcome will not only determine the availability of a potentially valuable new therapy but also shape the future landscape of nrSPMS treatment. Further research will be essential to fully understand the long-term benefits and risks of tolebrutinib and to identify the patients who are most likely to benefit from this innovative approach.
What are your thoughts on the evolving landscape of MS treatment? Share your perspectives in the comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
